Toolkits for the events that decide approvals
A toolkit is built around one high-stakes GxP event. It decodes the event, sequences readiness into phases with checklists, and gathers every SPEQ asset that bears on it — standards, interactive tools, templates, and topics — into one place. Topics explain subjects; a toolkit organises action against a date.
PAI & PLI Readiness Toolkit
A pending drug or biologics application can be delayed or withheld on the strength of one facility inspection. This toolkit decodes the FDA Pre-Approval Inspection (PAI) and the biologics Pre-License Inspection (PLI), maps each inspection objective to the readiness it demands, and sequences the work into five phases you can run against the date on your calendar.
DSCSA Readiness Toolkit
The Drug Supply Chain Security Act builds an interoperable, electronic, package-level system for tracing prescription drugs through the US supply chain — and since the stabilization period ended on November 27, 2024, its Enhanced Drug Distribution Security (EDDS) requirements are in effect. A trading partner that cannot exchange serialized transaction data, verify a product identifier, or authenticate its partners is no longer merely behind schedule; it is out of compliance and can be forced to stop shipping or receiving product. This toolkit decodes the DSCSA end state, maps each requirement to the readiness it demands, and sequences the work into phases you can run against the exemption date that applies to your trading-partner category.
Annex 1 CCS Implementation Toolkit
The 2022 revision of EU GMP Annex 1 turned contamination control from a set of discrete GMP practices into a single, documented, site-wide obligation: the Contamination Control Strategy (CCS). Annex 1 came into operation on 25 August 2023 (its lyophilisation provisions from 25 August 2024), and inspectors now expect a holistic CCS that assesses the collective effectiveness of every control and monitoring measure across your facility, utilities, processes, and people. This toolkit decodes the CCS requirement, frames it as three assessment pillars, sequences the build into phases you can run against your own site, and gathers every SPEQ asset that bears on it into one place.
Nitrosamine Risk-Assessment Toolkit
Since 2018 the discovery of N-nitrosamine impurities has forced recalls, import alerts, and supply disruptions across sartans, ranitidine, metformin, and a widening list of products — and the risk has since moved from a handful of small-molecule impurities to nitrosamine drug-substance-related impurities (NDSRIs) that can form from a drug substance's own amine structure. FDA now expects every applicant and manufacturer of chemically synthesised and certain biologic drugs to have run a documented three-step program — risk assessment, confirmatory testing, and reporting the changes made to control the risk. This toolkit decodes FDA's final guidance, maps each program step to the readiness it demands, and sequences the work into phases you can run against your portfolio and your reporting milestones.